Levetiracetam Actavis 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0038 
C.I.2.a - Change in the SPC, Labelling or PL of a 
21/06/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IAIN/0037/G 
This was an application for a group of variations. 
18/05/2023 
SmPC, Annex 
II and PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
IA/0036 
B.III.1.a.2 - Submission of a new/updated or 
08/12/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0035 
C.I.2.a - Change in the SPC, Labelling or PL of a 
29/06/2022 
15/06/2023 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IA/0034/G 
This was an application for a group of variations. 
21/02/2022 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IA/0033 
B.III.1.a.2 - Submission of a new/updated or 
28/05/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0032 
C.I.2.a - Change in the SPC, Labelling or PL of a 
25/05/2021 
14/06/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0031/G 
This was an application for a group of variations. 
11/01/2021 
14/06/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0030/G 
This was an application for a group of variations. 
11/05/2020 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0029 
B.II.b.3.a - Change in the manufacturing process of 
08/04/2020 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0028/G 
This was an application for a group of variations. 
06/04/2020 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
IB/0027 
C.I.2.a - Change in the SPC, Labelling or PL of a 
14/02/2020 
15/09/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0026 
B.II.b.3.z - Change in the manufacturing process of 
29/11/2019 
n/a 
the finished or intermediate product - Other variation 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/09/2019 
15/09/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
Page 4/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0024/G 
This was an application for a group of variations. 
28/06/2019 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/10/2018 
05/03/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0019/G 
This was an application for a group of variations. 
17/04/2018 
n/a 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0018/G 
This was an application for a group of variations. 
21/03/2018 
05/03/2019 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.3.a - Change in the manufacturing process of 
Page 6/12 
 
 
 
 
 
 
 
 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
N/0022 
Minor change in labelling or package leaflet not 
20/03/2018 
05/03/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0021/G 
This was an application for a group of variations. 
28/02/2018 
n/a 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0020/G 
This was an application for a group of variations. 
28/02/2018 
n/a 
B.II.e.z - Change in container closure system of the 
Finished Product - Other variation 
B.II.e.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
finished product - Other variation 
B.II.e.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Other variation 
IB/0017 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/03/2017 
07/03/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
R/0013 
Renewal of the marketing authorisation. 
21/07/2016 
08/09/2016 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Levetiracetam Actavis in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IA/0016 
B.III.1.a.2 - Submission of a new/updated or 
21/07/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IAIN/0015/G 
This was an application for a group of variations. 
11/03/2016 
08/09/2016 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
Page 8/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0014 
C.I.2.a - Change in the SPC, Labelling or PL of a 
24/02/2016 
08/09/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IAIN/0012/G 
This was an application for a group of variations. 
17/12/2015 
08/09/2016 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 9/12 
 
 
 
 
 
 
 
 
 
 
 
N/0011 
Minor change in labelling or package leaflet not 
07/09/2015 
08/09/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0010 
C.I.8.a - Introduction of or changes to a summary of 
20/05/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
N/0009 
Minor change in labelling or package leaflet not 
16/01/2015 
08/09/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0008 
B.III.1.a.1 - Submission of a new/updated or 
19/05/2014 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0007/G 
This was an application for a group of variations. 
02/05/2014 
16/12/2014 
SmPC and PL 
To update the SmPC and package leaflet with the tabulated 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
list of adverse reactions in section 4.8 with 
“hyponatraemia” and in section 4 of the PIL including 
“decreased blood sodium concentration”. 
To update 4.8 of the SmPC to include ‘drug reaction with 
eosinophilia and systematic symptoms (DRESS)’ as a rare 
adverse drug reaction. The package leaflet was updated 
accordingly. 
All changes have been made in line with the originator 
product.  
In addition the contact details of the local representatives 
in the package leaflet for the following countries: Belgium, 
Luxemburg and Greece were updated. Furthermore minor 
Page 10/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/12/2013 
16/12/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II and PL 
IAIN/0005/G 
This was an application for a group of variations. 
22/11/2013 
16/12/2014 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
N/0004 
Minor change in labelling or package leaflet not 
16/08/2013 
16/12/2014 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/07/2012 
31/10/2012 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Labelling and 
PL 
changes in the DK, EL, FI, HR, HU, IT, LV and PL PIL were 
introduced to be in line with the originator product. 
Page 11/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data are submitted by the MAH 
IB/0002 
C.I.2.a - Change in the SPC, Labelling or PL of a 
14/05/2012 
31/10/2012 
SmPC, Annex 
Update of SmPC and package leaflet following CHMP 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II, Labelling 
adoption of safety variations to the Marketing 
and PL 
Authorisations for Keppra, dated 22 September 2011. 
C.I.2 a) Variation related to significant modifications of the 
SmPC due in particular ot new quality, preclinical, clinical or 
Pharmacovigilance data. 
Additionally the Marketing Authorisation Holder took the 
opportunity to make formatting/editorial amendments. 
Page 12/12 
 
 
 
 
 
 
 
 
